In a recently completed study of once-a-day ertapenem versus piperacillin-tazobactam every 6 h in the treatment of complicated skin and skin-structure infections, 540 patients were randomized in a 1:1 ratio and assigned to 1 of 2 strata: those with a complicating underlying disease or all others. The most common infections in the study were deep soft-tissue abscess (18.9%), followed by diabetic lower extremity infection (18.1%); 7.0% of these were perineal cellulitis/abscess. With the exception of methicillin-resistant Staphylococcus aureus, almost all of the predominant aerobic pathogens were susceptible to both study drugs. Eighty-seven patients (16%) had у1 anaerobe identified in their baseline wound cultures, with a total of 232 anaerobic isolates. Of the 141 anaerobes tested for susceptibility, 97.2% were susceptible to ertapenem and 97.9% to piperacillintazobactam. Ertapenem had excellent in vitro activity against the most common aerobic pathogens and almost all anaerobes recovered from patients with infections of the skin and skin structures.
gram-positive and gram-negative aerobic and anaerobic bacteria, although the primary pathogens are Staphylococcus aureus and b-hemolytic streptococci; gramnegative nonfermenters, which generally are associated with nosocomial infections, are infrequently involved [1, 2] .
Empiric treatment of patients with CSSSIs requires coverage of a broad spectrum of potential pathogens, at least initially with parenteral therapy such as an extended-spectrum cephalosporin plus an agent like metronidazole or clindamycin that is effective against anaerobes or a b-lactam-b-lactamase inhibitor combination (e.g., piperacillin-tazobactam or ticarcillinclavulanate) [3] [4] [5] . These regimens, although known to be effective in the treatment of CSSSIs, require multiple daily parenteral doses and/or necessitate the administration of 11 drug. The possible limitations of such regimens may include a higher risk of infusionrelated complications, greater difficulty administering Downloaded from https://academic.oup.com/cid/article-abstract/35/Supplement_1/S119/443692 by guest on 25 December 2018 out-patient antibacterial therapy, and additional costs associated with the administration of multiple daily infusions.
Ertapenem (formerly MK-0826) is a once-a-day parenteral antimicrobial agent that can be used as monotherapy for the treatment of various community-acquired and mixed aerobicanaerobic infections. This is based on its spectrum of activity, reported clinical studies that used once-a-day dosing, pharmacodynamic studies in animals, and pharmacokinetic studies in both humans and animals [6] [7] [8] . Ertapenem is highly active in vitro against bacteria that typically are associated with CSSSI, such as staphylococci, streptococci, most pathogenic anaerobes, and members of the Enterobacteriaceae. However, it has minimal activity against enterococci and nonfermentative gramnegative bacilli, including Pseudomonas species, which generally are considered nosocomial pathogens, and, like other currently available b-lactam antimicrobials, ertapenem is not considered effective against methicillin-resistant S. aureus (MRSA).
To evaluate the efficacy of ertapenem given as a single daily dose for the treatment of CSSSI, clinical outcomes were compared with those associated with piperacillin-tazobactam administered every 6 h, in a multicenter study. The clinical results of that trial demonstrated that cure rates in the ertapenem and piperacillin-tazobactam treatment groups were equivalent [8] . The purpose of the present article is to provide an in-depth analysis of the microbiology of the infections in the randomized patients, with a detailed description of the anaerobic component, particularly susceptibilities of the different pathogens to various antimicrobial agents, including ertapenem.
MATERIALS AND METHODS
This double-blind, randomized study was conducted at 33 centers in the United States and 11 in South and Central America from April 1998 through November 1999. Hospitalized adults with a CSSSI were randomized (1:1) to treatment with either ertapenem 1 g iv once daily or piperacillin-tazobactam 3.375 g iv every 6 h. To ensure blinding, patients in the ertapenem group also received matching saline placebo infusions every 6 h. At entry, patients were assigned to 1 of 2 strata. Stratum 1 included patients with a complicating underlying disease, such as diabetes mellitus; patients with all other infections were in stratum 2.
Aerobic and anaerobic culture of purulent material or tissue collected from deep in the wound was performed on all patients at baseline. Identification of all pathogens (both aerobic and anaerobic) was required for all patients. Susceptibility testing was performed in the laboratories at the individual sites, with 2 exceptions: (1) susceptibility testing of anaerobes isolated from patients at sites in the United States was optional, depending on the usual practice of the local laboratory; and (2) testing of anaerobes from patients at international sites was performed at the R. M. Alden Research Laboratory and University of California, Los Angeles, Medical Center, Santa Monica. Specimens were sent by courier to that laboratory, where they were processed in the anaerobic chamber. Aspirates were thoroughly mixed before inoculation, tissue specimens were homogenized with a tissue grinder, and swab specimens were homogenized in a small amount of broth. Anaerobic media inoculated were supplemented Brucella blood, phenylethylalcohol blood, laked blood with kanamycin-vancomycin, and Bacteroides bile-esculin agars. Plates were incubated at 35ЊC for at least 5 days. Aerobic media included sheep blood and Rose agar, incubated in 5% CO 2 , and MacConkey agar incubated in ambient air. Anaerobic isolates were identified according to standard procedures and stored in skim milk at Ϫ70ЊC prior to susceptibility testing.
The susceptibility of aerobes to ertapenem and piperacillintazobactam was determined predominantly by disk diffusion, although some sites performed microdilution according to guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) [9, 10] . Isolates of staphylococci also were tested for susceptibility to oxacillin. MRSA were considered resistant to both ertapenem and piperacillin-tazobactam.
For anaerobes from international sites, MICs of ertapenem and several comparator antimicrobials were determined by agar dilution testing according to NCCLS protocol, using Brucella agar supplemented with vitamin K 1 , hemin, and laked sheep blood and an inoculum of 10 5 cfu/spot [11] . Plates were incubated for 44-48 h; the MIC was the lowest concentration of drug that completely inhibited or caused a marked change in the appearance of growth compared with the drug-free growth control plate. In all cases, only unique isolates (i.e., 1 particular species/patient) from patients were tested. Interpretive MIC break points for ertapenem against anaerobes were у16 mg/mL, resistant; 8 mg/mL, intermediate; and р4 mg/mL, susceptible.
RESULTS
The primary diagnoses of the 540 randomized patients are listed in table 1. Twenty-one percent of patients had an underlying complicating disease (stratum 1); the remainder were in stratum 2. The most common primary diagnosis was deep softtissue abscess (18.9%), followed by diabetic lower extremity infection (18.1%) and posttraumatic wound infection (17.0%).
A total of 871 bacterial pathogens were recovered from the 540 randomized patients; 181 patients (33.5%) had polymicrobial infections. The most common aerobic pathogen was S. aureus, which accounted for 24.1% of all isolates, followed by Streptococcus pyogenes (5.1%), Escherichia coli (4.5%), and Streptococcus agalactiae (4.1%). Of those tested for susceptibility to the study drugs at the local sites, most of which used disk An extensive comparative investigation of the antimicrobial susceptibilities of a subset of anaerobes, which consisted of all anaerobic isolates ( ) identified in specimens shipped n p 123 from international sites, to several drugs commonly used to treat anaerobic infections was performed at the R. M. Alden Research Laboratory. The countries from which these specimens were received and a summary of the culture results are shown in table 2. Susceptibility test results are listed in table 3. All isolates were susceptible to ertapenem, with the MIC 100 at 2 mg/mL. Piperacillin-tazobactam inhibited all except one Resistance to cefoxitin and clindamycin was evident among members of the B. fragilis group, and one isolate each of Peptostreptococcus magnus and P. anaerobius was also resistant to clindamycin. All of the gramnegative isolates were inhibited by metronidazole, but several gram-positive isolates, including Propionibacterium spp. and anaerobic streptococci, showed resistance.
DISCUSSION
The microbiology of the CSSSIs in the present study has both similarities to and differences from that of other reports. As in virtually all studies of skin and soft-tissue infections, S. aureus was the most common pathogen [1, 3, 4, 12] . In most studies, S. pyogenes ranks second in frequency, although some investigators did not list the individual species of streptococci, and in one study "Streptococcus milleri" was the second most frequently isolated pathogen [1] . Anaerobes always play an important role in complicated skin infections; peptostreptococci typically are the most common of the anaerobic isolates, as occurred in the present study. In some studies, especially those that have involved diabetic foot infections, anaerobes have accounted for a higher percentage of the total isolates than in the present study [2] . Although the specific reason for this difference is not known, variability in у1 of the factors associated with detection of anaerobes could have been involved: collection of an adequate specimen, use of an appropriate transport device, rapid transport of the specimen to the microbiology laboratory, timely culture of the specimen in the laboratory, and the use of adequate anaerobic culture and identification techniques. In our study, specimens from Latin American sites were shipped to a central laboratory (R. M. Alden Research Laboratory) in the United States, where laboratory personnel have expertise in the isolation and identification of anaerobes. The rate of recovery of anaerobes in the central laboratory was markedly higher (50.7%) than that in the local site laboratories, which brought the total anaerobe recovery rate down to only 16.1%. This suggests that factors other than transport time to the laboratory-media used, incubation environment, or lack of local expertise-had a greater impact on the detection and identification of anaerobes. The in vitro activity of ertapenem against the major aerobic pathogens in the current study was comparable to what other investigators have reported, with minor exceptions. In 2 recent studies of the activity of ertapenem, determined by broth microdilution testing, against clinical isolates collected in North America [13] and in Europe and Australia [14] , the 90% MICs for S. pyogenes ( in both studies) were 0.016 and n p 330 0.06 mg/mL (range, р0.008-0.25 mg/mL in both). For E. coli ( combined), 90% MICs were 0.016 mg/mL (range, n p 502 р0.008-0.5 mg/mL) and 0.03 mg/mL (range, 0.006-1 mg/mL). No isolates of S. pyogenes or E. coli in either study were intermediate or resistant to ertapenem. For the present clinical trial, the antimicrobial susceptibility of most isolates was determined by disk diffusion, and isolates that appeared to be intermediate or resistant after initial testing were not evaluated further to confirm the results.
In a recent comparison of the in vitro activities of ertapenem and other anaerobic agents, including those evaluated in the present study, against 1001 anaerobes isolated from intra-abdominal infections, ertapenem was highly active against all isolates except some B. wadsworthia (12 of 61 isolates were resistant), 3 isolates of Lactobacillus spp., and 1 Acidaminococcus fermentans [15] . As was seen in the current study, some grampositive anaerobes tested in the intra-abdominal study were resistant to metronidazole, and resistance to both clindamycin and cefoxitin occurred among the gram-negative anaerobes, particularly the B. fragilis group. The in vitro activity of ertapenem also has been studied in a large collection of clinical isolates (aerobes and anaerobes) from North America [13] and from Europe and Australia [14] . In both of the latter studies, which combined included 344 anaerobic isolates, the activity of ertapenem against anaerobes was excellent. Only one isolate of B. fragilis was resistant to ertapenem (as well as to all comparator drugs), and 1 C. difficile isolate was resistant to ertapenem, cefepime, and ceftriaxone.
In summary, CSSSIs in the community are typically poly microbic and are composed of both aerobic and anaerobic pathogens. Ertapenem was highly active in vitro against the major aerobic bacteria recovered from skin and skin structure infections in patients enrolled in the present clinical trial. Against anaerobic pathogens, the in vitro activity of ertapenem was as good as or better than that of several agents commonly used to treat anaerobic infections.
